Bolivia Pre-Marketing Notification for Medical Devices: Manual Section 5.9 and the Fifteen-Business-Day Timeline

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Section 5.9 of the Manual requires a notification obligation to AGEMED before commercialization begins, and the applicable time limit for this notification is fifteen business days. The GRZAN assessment is that this obligation sits, in procedural terms, after the sanitary registration has been obtained and before the first importation and sale, making it the final node that connects registration to market access. It belongs to a different chain from the customs clearance authorization certificate, known as CADA: CADA governs importation, while the notification governs placement on the market, and neither can be skipped in place of the other. A shipment that clears customs with a valid CADA but reaches customers without the pre-market notification having been made is still non-compliant at the point of sale, which is exactly where the exposure is most visible to inspectors and competitors alike.

The fifteen business days should be read as a planning quantity rather than a countdown that starts itself. Business days in Bolivia are affected by national holidays and local civic calendars, and a transit window that spans a holiday cluster consumes calendar time far faster than the working-day arithmetic suggests. GRZAN therefore recommends converting the limit into a calendar date on the launch plan at the moment the shipment is booked, using the Bolivian holiday calendar for the period, and treating that date as a hard gate for the bill of lading. If the notification cannot be submitted in time, the shipment date moves; the reverse, moving the notification to suit the shipment, is the failure pattern this article exists to prevent.

2. Legal basis

RegulationReference numberPublication dateProvision
Manual para Registro Sanitario de Dispositivos MédicosResolución Ministerial N° 010Current version as published on the AGEMED websiteSection 5.9
Manual para Registro Sanitario de Dispositivos MédicosResolución Ministerial N° 010Current version as published on the AGEMED websiteSection 5.7.1
Manual para Registro Sanitario de Dispositivos MédicosResolución Ministerial N° 010Current version as published on the AGEMED websiteSection 3.1.5
Form 011 (application form for the customs clearance authorization certificate)Form 011Current version issued by AGEMEDFull text

3. Expert insights

Insight one: the fifteen business days are the basis for planning the notification lead time. The limit applies to the notification under Section 5.9. The GRZAN practical estimate is that the notification should be completed before the first shipment departs, with the schedule counted backwards through the fifteen business days. If the notification is left until the goods have arrived at port, the advance-warning purpose of the requirement is lost, and the company is exposed during the entire maritime or air transit period with a marketed-in-intent product that has not yet been formally notified.

Insight two: the notification obligation depends in sequence on the registration number printing obligation. Section 5.7.1 requires the registration number to appear on the packaging, while the notification takes place before sale. The sensible operational order is: certificate issued, marking implemented, CADA processed, notification submitted, and only then selling. Placing the notification last in this chain ensures that by the time AGEMED is informed of commercialization, the product is genuinely in a sellable state, with compliant labeling and cleared import documentation already in place. The order also produces a clean paper trail: each step leaves a dated record that the next step presupposes, so the launch file reads as a sequence rather than a pile of simultaneous events.

Insight three: the notifying party is the license holder, but the timing is decided by the supply chain. The license holder submits the notification, yet the first-arrival date is fixed by the manufacturer and the logistics plan. Both parties must align on the first-shipment rhythm in advance, in writing, so that no gap arises in which goods have landed while the notification has not been sent. A shared shipment calendar, reviewed monthly, is the simplest control, and it also produces the documentary trail that demonstrates deliberate sequencing rather than accident. Where several launch lots are planned for the year, the calendar should list each lot separately, because the notification obligation attaches to commercialization as such, not to a single ceremonial first delivery.

4. Practical recommendations

  1. Make the pre-market notification a standalone milestone on the project Gantt chart, positioned before the first shipment, with its own owner and completion evidence rather than absorbing it into a general launch task.
  2. Plan backwards through the fifteen business days, and run the CADA process in parallel so that neither chain becomes the bottleneck for the other.
  3. Obtain written confirmation between manufacturer and importer on the first-shipment rhythm, naming the person responsible for the notification and the date on which it will be submitted for each launch lot.

Evidence matters as much as timing. The notification file should contain the submission record, the content of what was notified, and the product list it covered, so that when a later question arises about whether a given lot was within the notified scope, the answer is a document rather than a recollection. Where the portfolio grows through rectifications, the notification scope must be checked against the updated certificate, because a lot sold under an item added after the original notification may need its own notification. GRZAN reconciles the notification scope against the certificate at every rectification, a five-minute check that closes one of the quietest gaps in post-market compliance. Companies holding several certificates should keep one notification index covering all of them, listing for each certificate the date, scope, and receipt of every notification made, since the index turns an audit question into a lookup.

5. Verification checklist

  • □ Has the fifteen-business-day time limit for the Section 5.9 notification been confirmed?
  • □ Is the notification scheduled before the first shipment departs?
  • □ Has the notifying party, the license holder, been clearly designated?
  • □ Are the CADA process and the notification running in parallel?
  • □ Has the registration number marking been implemented before the notification?

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers, importers, and authorized representatives with sanitary registration, pre-market notifications, and post-market compliance in Bolivia. For assistance with this topic, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail